Akebia Therapeutics, Inc.
AKBA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $400,799 | $232,457 | $105,466 | $375,046 |
| - Cash | $51,870 | $42,925 | $90,466 | $149,800 |
| + Debt | $47,640 | $104,182 | $99,783 | $136,048 |
| Enterprise Value | $396,569 | $293,714 | $114,783 | $361,294 |
| Revenue | $160,180 | $194,623 | $292,484 | $211,650 |
| % Growth | -17.7% | -33.5% | 38.2% | – |
| Gross Profit | $97,003 | $120,474 | $269,988 | $130,156 |
| % Margin | 60.6% | 61.9% | 92.3% | 61.5% |
| EBITDA | -$13,721 | -$8,266 | $3,056 | -$189,908 |
| % Margin | -8.6% | -4.2% | 1% | -89.7% |
| Net Income | -$69,410 | -$51,925 | -$94,226 | -$282,024 |
| % Margin | -43.3% | -26.7% | -32.2% | -133.3% |
| EPS Diluted | -0.33 | -0.28 | -0.58 | -1.48 |
| % Growth | -17.9% | 51.7% | 60.8% | – |
| Operating Cash Flow | -$40,659 | -$23,384 | -$73,154 | -$252,965 |
| Capital Expenditures | -$33 | $0 | -$114 | -$59 |
| Free Cash Flow | -$40,692 | -$23,384 | -$73,268 | -$253,024 |